Shukla Akash, Patkar Shraddha, Sundaram Sridhar, Shah Samir R, Ingle Meghraj, Gupta Amit, Gopan Amrit, Kamat Mrunal, Mohanka Ravi, Singh Sandeep, Walke Swapnil, Pandey Vikas, Goel Mahesh
Department of Gastroenterology, Seth G.S Medical College and King Edward Memorial Hospital, Mumbai, India.
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1463-1473. doi: 10.1016/j.jceh.2022.05.006. Epub 2022 Jun 2.
Increasing incidence of hepatocellular carcinoma (HCC) in India is a matter of concern and need for adequate profiling and streamlining management strategies cannot be over-emphasized.
This is a prospective multi-centric observational cohort study comprising of an oncology center, one university tertiary hospital with specialized hepatology service, one public hospital with gastroenterology service, and a private liver transplant center located within a 3-km radius. The demographic and clinical parameters were recorded on a prospectively maintained database. The clinical profile, demographics, characteristics of HCC and the allocated treatment were noted and compared among the four centers.
In total, 672 patients were enrolled from June 2016 till January 2020. Abdominal pain (64.3%) and weight loss (47.3%) were the most common symptoms. Most common identified etiology was hepatitis B (39%). The cancer center received lesser patients with hepatitis C and those with advanced stage of HCC. The private transplant center reported the highest proportion of NASH, which was also significantly higher in those belonging to higher socioeconomic strata, and lowest proportion of alcoholic cirrhosis. Metastasis was seen in almost one-fifth (19%) cases at diagnosis. Portal vein thrombosis was evident in 40%. Adherence to treatment guidelines was seen in three-fourth cases (76%).
Hepatitis B is the most common underlying cause for HCC, whereas other causes like NASH are on the rise. Etiologic profile may vary with selective specialization of centers catering to patients with HCC. Adherence to guideline while allocating treatment was high among all centers with highest non-adherence in BCLC A.
印度肝细胞癌(HCC)发病率不断上升,令人担忧,因此,对其进行充分的特征分析并优化管理策略的必要性再怎么强调都不为过。
这是一项前瞻性多中心观察性队列研究,研究对象包括一个肿瘤中心、一家设有专业肝病科服务的大学三级医院、一家设有胃肠病科服务的公立医院以及一个位于半径3公里范围内的私立肝移植中心。人口统计学和临床参数记录在一个前瞻性维护的数据库中。记录并比较了四个中心的临床特征、人口统计学、HCC的特点以及分配的治疗方法。
2016年6月至2020年1月期间,共纳入672例患者。腹痛(64.3%)和体重减轻(47.3%)是最常见的症状。最常见的病因是乙型肝炎(39%)。癌症中心接收的丙型肝炎患者和HCC晚期患者较少。私立移植中心报告的非酒精性脂肪性肝炎(NASH)比例最高,在社会经济地位较高的人群中也显著更高,而酒精性肝硬化的比例最低。诊断时近五分之一(19%)的病例出现转移。40%的病例可见门静脉血栓形成。四分之三的病例(76%)遵循治疗指南。
乙型肝炎是HCC最常见的潜在病因,而其他病因如NASH呈上升趋势。病因特征可能因为HCC患者提供服务的中心的选择性专业化而有所不同。在所有中心中,治疗分配时遵循指南的比例较高,其中BCLC A期的不依从率最高。